ReviewEndocrinology and metabolism (Seoul, Korea)2021
Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Review in Endocrinology and metabolism (Seoul, Korea), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Real world incidence, predictors and outcomes of endocrine immune-related adverse events following immune checkpoint inhibitors.Human vaccines & immunotherapeutics · 2026Article
- Endocrinologist-Led Management of Endocrine Immune-Related Adverse Events: Real-World Evidence Supporting the Japan Endocrine Society Guidelines.Cancer medicine · 2026Observational
- Blood glucose variability in early-onset adrenocorticotropic hormone deficiency induced by immune checkpoint inhibitor therapy with continuous blood glucose monitoring: a case report.Diabetology international · 2026Article
- Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2025Article
- Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma.Therapeutics and clinical risk management · 2025Article
- Increased risk of hyperthyroidism induced by immune checkpoint inhibitors in patients with existing or prior Graves' disease: a nested prospective cohort study with propensity score matching.Frontiers in endocrinology · 2025Article
- Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer.BMC nephrology · 2024Article
- Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study.Nagoya journal of medical science · 2024Article
- A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab.Diabetology international · 2024Article
- Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.Cancer immunology, immunotherapy : CII · 2024Article
- A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma.Journal of translational internal medicine · 2024Article
- Article
- Immune-related thyroid dysfunction in patients with non-small cell lung cancer.Journal of thoracic disease · 2024Article
- Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction.Frontiers in endocrinology · 2024Article
- Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy.Cancers · 2023Review
- Severe thyrotoxicosis induced by tislelizumab: a case report and literature review.Frontiers in oncology · 2023Article
- Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report.Journal of diabetes investigation · 2023Article
- Biomarkers and risk factors for the early prediction of immune-related adverse events: a review.Human vaccines & immunotherapeutics · 2022Review
- Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-related adverse events (irAEs) affecting the endocrine glands are among the most frequent irAEs induced by immune checkpoint inhibitors (ICIs) and include hypopituitarism, primary adrenal insufficiency, thyrotoxicosis, hypothyroidism, hypoparathyroidism, and type 1 diabetes mellitus. Since the incidence and clinical features of endocrine irAEs vary according to the ICI used, it is important to understand the characteristics of these irAEs and to manage each one appropriately. Since some endocrine irAEs, including adrenal crisis and diabetic ketoacidosis, are potentially life-threatening, predicting the risk of endocrine irAEs before their onset is critical. Several autoantibodies have been detected in patients who develop endocrine irAEs, among which anti-thyroid antibodies may be predictive biomarkers of thyroid dysfunction. In this review, we describe the clinical features of each endocrine irAE induced by ICIs and discuss their potential biomarkers, including autoantibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.